Table 1 Baseline characteristics and outcomes of heart transplant recipients before and after matching categorized by Impella use
Before Matching | After Matching | |||||
|---|---|---|---|---|---|---|
Non-Impella (N = 171) | Impella (N = 42) | SMD | Non-Impella (N = 42) | Impella (N = 42) | SMD | |
Variables included in minimal sufficient adjustment set (propensity matching and inverse propensity weight) | ||||||
Gout | 39 (22.8) | 17 (40.5) | 0.387 | 16 (38.1) | 17 (40.5) | 0.049 |
CAD | 72 (42.1) | 8 (19) | 0.517 | 8 (19.0) | 8 (19.0) | < 0.001 |
Thiazides | 39 (22.8) | 19 (45.2) | 0.487 | 17 (40.5) | 19 (45.2) | 0.096 |
Loop diuretics | 156 (91.2) | 33 (78.6) | 0.359 | 33 (78.6) | 33 (78.6) | < 0.001 |
Variables for whom adjustments were not indicated as per DAG | ||||||
Age (years), median (IQR) | 59 (48, 65) | 61 (55, 68) | 0.371 | 57 (44, 65) | 61 (55, 67) | 0.570 |
BMI (kg/m2); median (IQR) | 28.4 (24.9, 32.3) | 28.8 (26, 33.5) | 0.006 | 28 (25, 33) | 28.8 (26, 33.5) | 0.041 |
Race; n (%) | 0.104 | 0.321 | ||||
White | 111 (64.9) | 25 (59.5) | 21 (50.0) | 25 (59.5) | ||
African American | 49 (28.7) | 14 (33.3) | 19 (45.2) | 14 (33.3) | ||
Asian Indian | 4 (2.3) | 1 (2.4) | 0 (0) | 1 (2.4) | ||
Caribbean Black | 3 (1.8) | 1 (2.4) | 1 (2.4) | 1 (2.4) | ||
Other | 3 (1.8) | 0 (0) | 1 (2.4) | 1 (2.4) | ||
Gender; n (%) | 0.551 | 0.500 | ||||
Male | 118 (69) | 38 (90.5) | 30 (71.4) | 38 (90.5) | ||
Female | 53 (31) | 4 (9.5) | 12 (28.6) | 4 (9.5) | ||
Comorbidities; n (%) | ||||||
Hypertension | 117 (68.4) | 31 (73.8) | 0.119 | 30 (71.4) | 31 (73.8) | 0.053 |
CHF | 164 (95.9) | 39 (92.9) | 0.133 | 39 (92.9) | 39 (92.9) | < 0.001 |
CKD | 86 (50.6) | 29 (69) | 0.390 | 20 (47.6) | 29 (60.0) | 0.445 |
Chronic Liver Disease | 15 (8.8) | 2 (4.8) | 0.160 | 3 (7.1) | 2 (4.8) | 0.101 |
Alcoholism | 8 (4.7) | 2 (4.8) | 0.004 | 3 (7.1) | 2 (4.8) | 0.101 |
DM2 | 79 (46.2) | 24 (57.1) | 0.220 | 16 (38.1) | 24 (57.1) | 0.389 |
Outpatient Antigout Medication; n (%) | 18 (10.5%) | 12 (28.6%) | 0.467 | 9 (21.4) | 12 (28.6%) | 0.166 |
Colchicine | 5 (2.9) | 6 (14.3) | 4 (9.5) | 6 (14.3) | ||
Allopurinol | 15 (8.8) | 10 (23.8) | 6 (14.3) | 10 (23.8) | ||
Febuxostat | 1 (0.6) | 2 (4.8) | 1 (2.4) | 2 (4.8) | ||
Inpatient medication; n (%) | ||||||
Low-dose salicylates | 97 (56.7) | 38 (90.5) | 0.829 | 22 (52.4) | 38 (90.5) | 0.930 |
Steroids | 136 (79.5) | 34 (80.9) | 0.036 | 36 (85.7) | 34 (80.9) | 0.128 |
Cyclosporine | 9 (5.3) | 5 (11.9) | 0.239 | 6 (14.3) | 5(11.9) | 0.071 |
Tacrolimus | 159 (93) | 34 (80.9) | 0.363 | 38 (90.5) | 34 (80.9) | 0.275 |
Gout Flare | 9 (5.3) | 13 (30.9) | 0.708 | 3 (7.1) | 13 (30.9) | 0.636 |
Outcomes | ||||||
Hospital LOS (days); median (IQR) | 38.0 (22.0, 65.5) | 50.5 (42.0, 76.8) | 0.367 | 38 (26, 55) | 50.5 (42.0, 76.8) | 0.533 |
ICU LOS (days); median (IQR) | 6.0 (4.0, 13.5) | 25.5 (14.3, 42.3) | 0.870 | 6 (4, 11) | 25.5 (14.3, 42.3) | 0.904 |
IMV, n(%) | 140 (81. 9%) | 34 (80.9%) | 0.024 | 32 (76.2) | 34 (80.9) | 0.116 |
Mortality, n(%) | 26 (15.2%) | 4 (9.5%) | 0.173 | 4 (9.5) | 4 (9.5) | < 0.001 |